

INFORMATION RELATING TO THE HOLDING OF THE COMBINED SHAREHOLDERS' MEETING OF 24 MAY 2022

FORMALITIES FOR MAKING AVAILABLE AND CONSULTING PREPARATORY DOCUMENTS TO THE MEETING

Boulogne-Billancourt (France), 3 May 2022 – The Shareholders of the Company are invited to participate in the Combined Shareholders' Meeting of Ipsen (Euronext: IPN; ADR: IPSEY) to be held on Tuesday, 24 May 2022 at 3:00 p.m. (Paris time) at the *Salons de l'Hôtel des Arts et Métiers, 9 bis avenue d'Iéna, 75116 Paris*.

The preliminary notice of the Meeting ("*avis de réunion*") was published in the *Bulletin des Annonces Légales Obligatoires* (BALO) of 15 April 2022 and the notice of Meeting ("*avis de convocation*") will be published in the BALO on 6 May 2022. These documents, as well as the Convening notice (including the agenda, the draft resolutions and the conditions regarding attendance and vote), are also available on Ipsen's website at the following address: www.ipсен.com, under the Investors / Shareholders' Meetings section. Documents and information relating to this Meeting are made available to shareholders under the legal and regulatory conditions in force.

The Shareholders will be asked to approve in particular the following resolutions:

- The payment of a dividend of €1.20 per share for the financial year 2021, the ex-date being set on 31 May 2022 and the dividend payment on 2 June 2022;
- The renewal of the terms of office of Highrock S.à.r.l., Mr. Paul SEKHRI and Mr. Piet WIGERINCK as Directors for a term of 4 years, as well as the ratification of the temporary appointment of Mrs. Karen WITTS as a Director, maintaining the independence Directors' rate within the Board of Directors at a third in accordance with the Afep-Medef Code and each gender's proportion at more than 40% in accordance with the law (the Director representing the employees being not taken into account in these rates).

In accordance with applicable regulatory provisions:

- Registered shareholders may, up to the fifth day (inclusive) before the Meeting, request from the Company to send these documents, where appropriate at his/her express request by electronic means. For holders of bearer shares, the exercise of this right is subject to the presentation of a shareholding certificate (*attestation de participation*) in the bearer securities accounts managed by the authorized intermediary.
- Any shareholder may consult these documents at the Company's headquarters.

In the context of the Covid-19 pandemic, the Company may have to modify the procedures for holding and/or participating in the Shareholders' Meeting of 24 May 2022. Shareholders are invited to regularly consult the page dedicated to the 2022 Shareholders' Meeting on the Company's website (www.ipсен.com, section Investors / Shareholders' Meeting) in order to have access to all the updated information concerning the Shareholders' Meeting and the final terms of participation.

Ipsen

Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company's research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen, excluding its Consumer HealthCare business, has around 4,500 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipсен.com.